Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 10, 2022 09:00 ET | Source: EvolveImmune

EvolveImmune Therapeutics Reports Preclinical Data Highlighting Deep and Durable Anti-Tumor Efficacy with EV-104 in Presentation at 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Poster Spotlights CD2 Pathway as a Differentiated T Cell Costimulation Approach for the Treatment of Solid and Hematological Malignancies Modular Platform Being Leveraged to Advance Broad Pipeline of...
October 24, 2022 07:00 ET | Source: EvolveImmune

EvolveImmune Therapeutics Presents Promising Preclinical Data from Novel Costimulatory T Cell Engager Platform at American Association for Cancer Research (AACR) Special Conference on Tumor Immunology and Immunotherapy

EVOLVE™ Platform Shows Promise as a Differentiated T Cell Costimulation Approach for the Treatment of Solid and Hematological Malignancies Presentation Highlights CD2 as an Optimal Costimulatory...
October 18, 2022 07:00 ET | Source: EvolveImmune

EvolveImmune Therapeutics to Present New Preclinical Data from Novel Costimulatory T Cell Engager Platform at Upcoming Scientific Conferences

EVOLVE™ Platform Shows Promise as a Differentiated T Cell Costimulation Approach for the Treatment of Solid and Hematological Malignancies Poster Presentations Scheduled for American Association...
July 07, 2022 07:00 ET | Source: EvolveImmune

EvolveImmune Therapeutics Appoints Jay Fine, Ph.D., as President of Research and Development

BRANFORD, Conn., July 07, 2022 (GLOBE NEWSWIRE) -- EvolveImmune Therapeutics, an immuno-oncology company developing first-in-category, multifunctional cancer biotherapeutics, today announced the...

keyboard_arrow_left Previous Page